Tarran, Robert
- Eldec Pharmaceuticals, Inc. (no department on record)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
FY2022 NIH rank #7,052
- Rising Star
- Sustained Excellence
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2022Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2022
Linked Award Amount
$1.3M
Full award amounts, FY2022
Award Records
2
Records listing this PI
Award-Linked Rank
#7,052
By linked amount among FY2022 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2022 award records by amount
NIH award records listing Tarran, Robert as a PI. Multi-PI records show the full award amount for context.
- 5R42AI155107-03R42Contact PIELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung$988.2Kaward amount
- 1R41AI162083-01A1R41Contact PINovel Peptide Fusion Inhibitors for the Treatment of COVID-19$300Kaward amount
Award organization
Organizations that administered FY2022 awards listing Tarran, Robert as a PI.
FY2022 award administered by Eldec Pharmaceuticals, Inc. (NC).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardEldec Pharmaceuticals, Inc.
- 2012$500K Cumulative Funding
- 2013$1M Cumulative Funding
- 2013$2M Cumulative Funding
- 2013$5M Cumulative Funding
- 2013Entered Top 50% NationallyRanked #769
- 2013Entered Top 25% NationallyRanked #769
- 2013Entered Top 10% NationallyRanked #769
- 2013Entered Top 5% NationallyRanked #769
- 2015$10M Cumulative Funding
- 2022$25M Cumulative Funding